Price
No data yet.
Social Signal Score
Analyst Ratings
36 analystsRevenue
$192.40M+181.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frank D. Lee
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 827
- Beta
- 0.25
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.98
Financials
Revenue
$192.40M+181.5%Net Income
$4.65MEBITDA
$25.60MFree Cash Flow
$56.12M+621.6%EPS (diluted)
$0.12Shares Outstanding (diluted)
40.30M+8.0%Operating Expenses
$122.05MCash & Debt
$251.03MReturn of Capital
$0.00Revenue by Segment (annual)
$1.42BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $726.41M | $7.03M | $0.16 |
| 2024 | $700.97M | $-99.56M | $-2.15 |
| 2023 | $674.98M | $41.95M | $0.91 |
| 2022 | $666.82M | $15.91M | $0.35 |
| 2021 | $541.53M | $41.98M | $0.95 |
| 2020 | $429.65M | $145.52M | $3.41 |
| 2019 | $421.03M | $-11.02M | $-0.27 |
| 2018 | $337.28M | $-471.0K | $-0.01 |
| 2017 | $286.63M | $-42.61M | $-1.07 |
| 2016 | $276.37M | $-37.95M | $-1.02 |
| 2015 | $249.00M | $1.86M | $0.05 |
| 2014 | $197.67M | $-13.72M | $-0.39 |
| 2013 | $85.55M | $-63.91M | $-1.93 |
| 2012 | $39.08M | $-52.28M | $-1.72 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.23
- Implied price
- $4.17
- Return from $36.30
- -35.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.08 — -94.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -45.7% | -43.2% | -41.1% | -39.3% | -37.6% |
| 3.0% | -42.9% | -40.3% | -38.1% | -36.2% | -34.5% |
| 8.0% | -40.2% | -37.4% | -35.1% | -33.1% | -31.3% |
| 13.0% | -37.4% | -34.5% | -32.1% | -30.0% | -28.1% |
| 18.0% | -34.6% | -31.6% | -29.1% | -26.9% | -24.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsbusinesswire.com·6h ago·Neutral
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or…
View source ↗ - Newsglobenewswire.com·1d ago·Positive
…nd practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, and Caregiver Action Network (CAN), the nation's leading family caregiver organization, today announced findings from Ready, Set, Recover, an initiative examining family caregivers' experiences with surge…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
…nds patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.73 per share
Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.73 vs $0.65beat
- Thu, Apr 30$0.60 vs $0.61miss
- Thu, Feb 26$0.57 vs $0.85miss
- Thu, Nov 6$0.70 vs $0.65beat
- Tue, Aug 5$0.74 vs $0.72beat
- Thu, May 8$0.62 vs $0.57beat
Estimates and results for PCRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PCRX officers and directors.
- Bought
- —
- Sold
- $3.2m
0 trades
20 trades
- Slonin Jonathansold
- Riker Laurensold
- Williams Kristensold
- Cross Shawnsold
- Cross Shawnsold
- Cross Shawnsold
- Slonin Jonathansold
- Froimson Marksold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Jun 23, 2021 (48d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Jun 12, 2021 (53d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (644d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (560d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (526d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (49d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (645d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (123d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.